Table 8

Treatment recommendations for hematologic disorders review articles in core medical journals 1997 to 2007

Hematologic disorderYears 1997-1999
Years 2000-2007
Relevant reviews, no.*Met criteria, no. (%)Relevant reviews, no.*Met criteria, no. (%)
SCD, opioid therapy N/A N/A 0 (0) 
SCD, hydroxyurea 1 (25) 0 (0) 
VWD 2 (100) 2 (100) 
Hemophilia A 0 (0) 
β-Thal 1 (50) 1 (50) 
TTP 1 (100) 3 (75) 
ITP 1 (100) 3 (100) 
AML 1 (50) 3 (100) 
Hematologic disorderYears 1997-1999
Years 2000-2007
Relevant reviews, no.*Met criteria, no. (%)Relevant reviews, no.*Met criteria, no. (%)
SCD, opioid therapy N/A N/A 0 (0) 
SCD, hydroxyurea 1 (25) 0 (0) 
VWD 2 (100) 2 (100) 
Hemophilia A 0 (0) 
β-Thal 1 (50) 1 (50) 
TTP 1 (100) 3 (75) 
ITP 1 (100) 3 (100) 
AML 1 (50) 3 (100) 

Medline/PubMed searches were performed from the National Library of Medicine website (http://www.nlm.nih.gov) on August 26, 2007, using as keywords the specific hematologic disorder + therapy/therapeutics. Searches were then limited to review articles involving human subjects, written in English, and published in core medical journals during the last 10 years. Pediatric journals were excluded except for the treatment of thalassemia and hemophilia A. See Appendix 2 for specific references.

SCD indicates sickle cell disease; VWD, von Willebrand disease; β-Thal, β-thalassemia major; TTP, thrombotic thrombocytopenic purpura; ITP, immune (or idiopathic) thrombocytopenic purpura; and AML, acute myeloid leukemia.

*

Indicates review articles that at least in part addressed treatment of a given disorder.

See Table S1 for criteria for each disorder.

Review articles addressing opioid use for pain control in VOC prior to 2000 were not included since they antedated publication of the first treatment guideline.

or Create an Account

Close Modal
Close Modal